Cost-utility analysis of botulinum toxin type a products for the treatment of cervical dystonia

American Journal of Health-System Pharmacy

Volumn 72, Issue 4, 2015, Pages 301-307

  Kazerooni, Rashid ^a   Broadhead, Christine ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b SHARP HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; CERVICAL DYSTONIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; HUMAN; MONTE CARLO METHOD; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; COST; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; ECONOMICS; PSYCHOLOGY; TORTICOLLIS; TREATMENT OUTCOME;

BOTULINUM TOXINS, TYPE A; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HUMANS; NEUROMUSCULAR AGENTS; QUALITY-ADJUSTED LIFE YEARS; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84921710189     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140276     Document Type: Article

References (34)

1. Fahn S, Marsden CD, Calne DB. Movement disorders 2. London: Butterworth; 1987:332-58.
2. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991; 6:119-26.
3. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991; 41:1088-91.
4. Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain. 1997; 69:279-86.
5. Tarsy D, First ER. Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord. 1999; 14:1043-5.
6. Van Herwaarden GM, Anten HW, Hoogduin CA et al. Idiopathic spasmodic torticollis: a survey of clinical syndromes and patients' experiences. Clin Neurol Neurosurg. 1994; 96:222-5
7. Hilker R, Schischniaschvili M, Ghaemi M et al. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001; 71:193-9.
8. Camfield L, Ben-Shlomo Y, Warner TT, for the Epidemiological Study of Dystonia in Europe Collaborative Group. Impact of cervical dystonia on quality of life. Mov Disord. 2002; 17:838-41.
9. Nutt JG, Muenter MD, Aronson A et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988; 3:188-94.
10. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007; 13:411-6.
11. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995; 45:1743-6.
12. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004; 75:951-7.
13. Brans JW, Lindeboom R, Snoek JW et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective randomized, double-blind controlled trial. Neurology. 1996; 46:1066-72.
14. Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. Drugs. 2001; 61:1921-43.
15. Costa J, Espirito-Santo C, Borges A et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2005; 1:CD003633.
16. Simpson LL. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981; 33:155-88.
17. Naumann M, Yakovleff A, Durif F, for the BOTOX Cervical Dystonia Prospective Study Group. A randomized, doublemasked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002; 249:57-63.
18. Tsui JK, Eisen A, Stoessl AJ et al. Doubleblind study of botulinum toxin in spasmodic torticollis. Lancet. 1986; 2:245-7.
19. Zoons E, Dijkgraaf MG, Dijk JM et al. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmacoeconomic value. J Neurol. 2012; 259:2519-26.
20. Ferreira JJ, Bhidayasiri R, Colosimo C et al. Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol. 2012; 27:225-30.
21. Ipsen Biopharmaceuticals. Dysport (abobotulinumtoxinA) prescribing information. www.dysport.com/ps/PDFs/Dysport-Patiens-PI-Aug2012.pdf (accessed 2014 Jan 10).
22. Merz Pharmaceuticals. Xeomin (incobotulinumtoxinA) prescribing information. www.xeomin.com/files/Xeomin-PI.pdf (accessed 2014 Jan 10).
23. Marchetti A, Magar R, Findley L et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005; 20:937-44.
24. Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry. 1998; 64:13-7.
25. Comella C, Jankovic J, Truong DD et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN, Botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neuro Sci. 2011; 308:103-9.
26. Department of Veterans Affairs. Federal supply schedule: drug pharmaceutical prices. www.pbm.va.gov/drugpharmaceuticalprices.asp (accessed 2013 Oct 1).
27. Centers for Medicare and Medicaid Services. Reimbursement schedule. www.cms.gov/apps/physician-fee-schedule/ (accessed 2013 Sep 15).
28. Briggs A, Sculpher M, Claxton K. Decision modeling for health economic evaluation. Oxford: Oxford Univ. Press; 2006.
29. Shaw JW, Zachry WM. Application of probabilistic sensitivity analysis in DA modeling. Formulary. 2002; 37:32-40.
30. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford Univ. Press; 2000:182-202.
31. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies, and frequently asked questions. Health Econ. 2004; 13:405-15.
32. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005; 187:106-8.
33. Allergan. 2010 Annual report. www.allergan.com/assets/pdf/2010AnnualReport.pdf (accessed 2014 Jan 17).
34. Allergan. 2012 Annual report. www.allergan.com/assets/pdf/2012AnnualReport.pdf (accessed 2014 Jan 17).